Switching Patients from Originator to Biosimilar Medications in Rheumatoid Arthritis: Limiting the ‘Nocebo’ Effect
Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality. Since their introduction, various sources of data have become available to help physicians make knowledgeable decisions about their use. For example,...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2017-08-01
|
| Series: | European Medical Journal Rheumatology |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/rheumatology/symposium/switching-patients-from-originator-to-biosimilar-medications-in-rheumatoid-arthritis-limiting-the-nocebo-effect/ |